Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...
Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Earlier this month the Mathematics Institute at Uppsala University hosted a conference called Categorification in Algebra and Topology, clearly a theme close to our collective heart. As yet there are ...